Milestone
3.3.b
Rapid endpoint identification
Not started
Develop a process involving cross-cutting experts and regulators for rapidly identifying and agreeing on standardized clinical and/or immunologic end points that can be used to capture vaccine efficacy quickly after the emergence of a novel coronavirus.